Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies that address high unmet medical needs and improve the lives of patients. The company's mission is rooted in scientific rigor and patient-centric innovation, primarily focusing on central nervous system (CNS) disorders and rare diseases. Headquartered in Washington, D.C., USA, Vanda Pharmaceuticals operates from 2200 Pennsylvania Avenue Northwest, Suite 300E.

Vanda's commercial portfolio includes several key products. HETLIOZ (tasimelteon) is approved for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome. Fanapt (iloperidone) is utilized for the treatment of schizophrenia and bipolar I disorder. PONVORY (ponesimod) addresses inflammatory/autoimmune disorders, including multiple sclerosis. Most recently, the company launched NEREUS (tradipitant) for the prevention of vomiting induced by motion in adults.

In recent news, Vanda Pharmaceuticals announced the commercial availability of NEREUS (tradipitant) in the U.S. in May 2026, marking the first new pharmacologic treatment for motion sickness in over 40 years, following its FDA approval on December 30, 2025. The company continues to advance its pipeline, with NEREUS also in clinical development for gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. Mihael H. Polymeropoulos, MD, serves as the President, CEO, and Chairman of the Board, having founded the company in 2003. Vanda Pharmaceuticals is positioned as a small-cap biopharmaceutical firm with a strategic focus on high-risk, high-reward drug development in niche patient populations, with recent product launches and a robust pipeline expected to contribute to future growth and a transition towards profitability.